GlobeNewsWire · 18 Aug 2026positive
SciSparc's subsidiary NeuroThera Labs completed a C$5.4 million financing round, with SciSparc investing C$2.7 million. Following the financing, SciSparc holds approximately 44.6% of NeuroThera's issued and outstanding common shares, with its stake valued at approximately C$30 million.
Why it matters — The financing and the C$30 million valuation of SciSparc's 44.6% stake in NeuroThera provide a concrete indicator of the subsidiary's value within SciSparc's portfolio.
TheNewswire · 18 Aug 2026positive
NeuroThera Labs Inc., a majority-owned subsidiary of SciSparc Ltd., closed the final tranche of its non-brokered private placement, raising C$2,700,000 through the sale of 22,500,000 units at C$0.12 per unit. Each unit comprises one common share and one common share purchase warrant exercisable at US$0.115 per share until August 17, 2029, subject to an acceleration provision should NeuroThera's securities be approved for trading on the Nasdaq Stock Market.
Why it matters — As a majority-owned subsidiary of SciSparc, NeuroThera's successful completion of this financing provides additional funding for its clinical-stage operations, which is relevant to SPRC shareholders following the company's development.
TheNewswire · 12 Aug 2026neutral
NeuroThera Labs Inc., a majority-owned subsidiary of SciSparc Ltd., announced it closed the first tranche of its non-brokered private placement, raising C$2,700,000 through the sale of 22,500,000 units at C$0.12 per unit. Each unit consists of one common share and one non-transferable unit warrant exercisable at US$0.115 per share until August 12, 2029, with an acceleration provision tied to a potential Nasdaq listing.
Why it matters — As NeuroThera is a majority-owned subsidiary of SciSparc, the successful closing of this financing strengthens the subsidiary's financial position and could be relevant for SPRC watchers tracking its operations under Nasdaq-listed governance.
GlobeNewsWire · 12 Aug 2026positive
SciSparc announced that its subsidiary NeuroThera Labs Inc. was granted a patent by the Japanese Patent Office for its proprietary pharmacological combination titled "Compositions and Methods for Potentiating Derivatives of 4-Aminophenols," as announced by NeuroThera on Aug. 12, 2026.
Why it matters — The grant of a Japanese patent adds intellectual property protection for NeuroThera's therapeutic combination, a key asset within SciSparc's portfolio.
TheNewswire · 12 Aug 2026positive
NeuroThera Labs Inc., a majority-owned subsidiary of SciSparc Ltd., announced that the Japanese Patent Office granted it a patent for its pharmacological combination titled "Compositions and Methods for Potentiating Derivatives of 4-Aminophenols." The patent covers combinations of 4-aminophenol derivatives (including paracetamol) and N-acylethanolamines designed to enhance analgesic and antipyretic performance, potentially enabling lower effective dosing and mitigating dose-related side effects.
Why it matters — For SciSparc watchers, the grant of this Japanese patent strengthens the intellectual property position of its majority-owned subsidiary NeuroThera Labs, which is progressing as a clinical-stage asset within SciSparc's portfolio.
